Developmental IL-6 Exposure Favors Production of PDGF-Responsive Multipotential Progenitors at the Expense of Neural Stem Cells and Other Progenitors

Ekta Kumari,1,3 Fernando J. Velloso,1,3 Azadeh Nasuhidehnavi,1 Aditya Somasundaram,1 Vibha H. Savanur,1 Krista D. Buono,2 and Steven W. Levison1,*

1Department of Pharmacology, Physiology and Neuroscience, Rutgers Biomedical Health Sciences of Rutgers University, 205 South Orange Ave. Newark, NJ 07103, USA
2ICON Laboratory Services, Farmingdale, NY 11735, USA
3Co-first author
*Correspondence: levisosw@rutgers.edu
https://doi.org/10.1016/j.stemcr.2020.03.019

SUMMARY

Interleukin-6 (IL-6) is increased in maternal serum and amniotic fluid of children subsequently diagnosed with autism spectrum disorders. However, it is not clear how increased IL-6 alters brain development. Here, we show that IL-6 increases the prevalence of a specific platelet-derived growth factor (PDGF)-responsive multipotent progenitor, with opposite effects on neural stem cells and on subsets of bipotential glial progenitors. Acutely, increasing circulating IL-6 levels 2-fold above baseline in neonatal mice specifically stimulated the proliferation of a PDGF-responsive multipotent progenitor accompanied by increased phosphorylated STAT3, increased Fbxo15 expression, and decreased Dnmt1 and Tlx expression. Fate mapping studies using a Nestin-CreERT2 driver revealed decreased astrogliogenesis in the frontal cortex. IL-6-treated mice were hyposmic; however, olfactory bulb neuronogenesis was unaffected. Altogether, these studies provide important insights into how inflammation alters neural stem cells and progenitors and provide new insights into the molecular and cellular underpinnings of neurodevelopmental disorders associated with maternal infections.

INTRODUCTION

A large number of studies support the view that maternal infection, or maternal immune activation (MIA), is a significant contributor to the pathology of autism spectrum disorders (ASD) (Atladottir et al., 2010; Zerbo et al., 2015). Indeed, a recent study of more than 2 million Swedish women found that having an infection during pregnancy increased the risk of having a child with autism by 37% (Lee et al., 2015). Observations in ASD and models of MIA (Smith et al., 2007) are analogous to those seen in fetal inflammatory response syndrome, where one of the diagnostic markers is an increase in interleukin-6 (IL-6) concentration (Gomez et al., 1998). In particular, studies have established that the levels of IL-6 are increased in maternal serum, amniotic fluid, and serum of children subsequently diagnosed with ASD (Ashwood et al., 2011; Croonenberghs et al., 2002). Moreover, independent studies have established that children and adults with ASD have higher circulating IL-6 levels compared with controls (Ashwood et al., 2011). These increases are associated with irritability, impaired communication and sociabilization skills and intelligence. Accordingly, IL-6 is increasingly being used as a biomarker for ASD (Yang et al., 2015).

Infections in pregnant mice and rats, can be mimicked by administering agents that activate the maternal immune system, such as maternal injections of the synthetic double-stranded RNA poly(I:C) (to evoke an anti-viral inflammatory response) or by administering lipopolysaccharide (LPS) (to evoke an anti-bacterial inflammatory response). These immune activators increase circulating levels of cytokines, including IL-6 (Kirsten et al., 2018) that can cross the placenta and the fetal blood-brain barrier (Aaltonen et al., 2005; Zaretsky et al., 2004) to affect the developing brain (Wu et al., 2017). Studies in mice have shown that these immune activators elicit many of the cardinal behavioral features of autism, as well as neuropathological aberrations (Malkova et al., 2012; Smith et al., 2007). However, it is not clear how these cytokines alter the trajectory of neural development.

At present, the majority of animal models of MIA used to study autism have manipulated the maternal immune system at time points that correspond to the first trimester of human development (Malkova et al., 2012; Meyer et al., 2006; Smith et al., 2007). Such studies will affect the primitive neural stem cells (NSCs) and neural stem and progenitors (NSPs) that reside in the neuroepithelium known as the ventricular zone (VZ). However, epidemiological studies on ASD have shown associations between maternal infections in the late second trimester and early third trimester and incidence of ASD (Zerbo et al., 2015), when proliferative cells in the VZ are declining in number, and the subventricular zone (SVZ) is expanding rapidly to peak in size during early postnatal development. Mice are born precociously, thus the brain of a newborn mouse is equivalent to that of an early third-trimester human infant.
(Salmaso et al., 2014). Therefore, to model the effects of maternal inflammation in mice using a more appropriate animal model, we manipulated the levels of IL-6 in the neonatal mouse and asked how this affected the pool of NSCs and progenitors in the SVZ of the forebrain.

**RESULTS**

**Modeling Maternal Infections by Systemically Injecting IL-6**

Previous studies have measured 2- to 3-fold increases in the blood plasma IL-6 levels in children with ASD (Ashwood et al., 2011). Therefore, to determine the dose of IL-6 needed to mimic the increased levels of IL-6 seen in children who will develop ASD, we injected neonatal mice with four doses of IL-6 (40, 75, 150, and 400 ng) versus PBS twice on postnatal day 4 (P4) and once on P5 and then measured plasma levels of IL-6 2 h after the third injection. We used this paradigm to produce sustained increased levels of IL-6 for at least 36 h. Mice that received 40 ng of recombinant mouse IL-6 (rmIL-6) had blood plasma levels of $31 \pm 10$ pg/mL versus $21 \pm 4.3$ pg/mL in PBS-injected littermates (1.4-fold increase). Mice that received 75 and 150 ng had blood plasma levels of $43 \pm 6.7$ pg/mL (2-fold increase) and $58 \pm 12$ pg/mL (2.7-fold increase) of IL-6, respectively. Finally, mice that received 400 ng IL-6 had $185 \pm 32$ pg/mL in blood plasma (8.6-fold increase) (Figure 1A; Table S1). The doses of 75 and 150 ng of IL-6 resulted in blood plasma levels similar to those observed in ASD children. To determine whether these doses were eliciting a systemic response, we measured the body temperature of mice that received 75 and 150 ng of IL-6 1 h after the last injection. The 2- to 3-fold increase in circulating IL-6 caused a small but significant increase in body temperature (Figure 1B). We decided to use 75 ng of IL-6 for subsequent in vivo studies, as it elicited a systemic response inside the range of the blood plasma levels observed in ASD children (Ashwood et al., 2011).

**Elevated Level of IL-6 Increases the Proliferation of PDGF-Responsive Multipotential Progenitors In Vivo**

We hypothesized that systemically elevating IL-6 would directly affect the NSPs in the developing mouse brain. Using a multi-marker flow panel comprised of CD133/CD140a/NG2/LeX, we have previously established that there are seven subsets of neural progenitors as well as NSCs in the neonatal mouse SVZ (Buono et al., 2012). When isolated by fluorescence-activated cell sorting (FACS) these NSCs and progenitors have different potencies and growth factor responsiveness in vitro (Table S2). To establish how increased levels of IL-6 would affect these NSPs individually in vivo, we injected 75 ng of IL-6 twice on P4 mice and once on P5 mice (Figure 2A) and analyzed changes in NSP proliferation using ethynyl deoxyuridine (EdU) incorporation. Edu (50 mg/kg) was injected twice at intervals of 2 and 4 h before euthanizing the mice for flow cytometry. The gating scheme for the flow cytometry is shown in Figures 2B and 2C. A significant increase was detected in the proliferation of the platelet-derived growth factor (PDGF) and fibroblast growth factor 2 (FGF-2)-responsive multipotential progenitors (PFMPs) (Figure 2D; PBS: $8.6 \% \pm 3.45 \%$, IL-6: $22.2 \% \pm 5.32 \%; p < 0.05$) compared to controls. However, there was no significant change in Edu incorporation into other SVZ cells (NSC, PBS: $14.6 \% \pm 9.09 \%$, IL-6: $15.45 \% \pm 8.94 \%$; multipotential progenitor-1 [MP1], PBS: $6.96 \% \pm 3.37 \%$, IL-6: $7.76 \% \pm 3.97 \%$).
3.98%; MP2, PBS: 17.88% ± 10.03%, IL-6: 30.83% ± 8.47%;

bipotential neuron astrocyte progenitor [BNAP], PBS: 6.64% ± 4.94%, IL-6: 7.99% ± 3.23%;
glial-restricted progenitor 3 [GRP3], PBS: 4% ± 0.40%, IL-6: 3.19% ± 0.22%;

GRP2, PBS: 3.88% ± 0.61%, IL-6: 5.48% ± 0.99%).

**IL-6 Alters Gene Expression of PFMPs In Vitro**

Whereas others have described PDGF-responsive multipotential progenitors, to date there is very little known about their transcriptome. Therefore, to begin to understand which transcription factors might be involved in the increase in PFMPs, neurospheres were established *in vitro* and PFMPs were sorted as described above. Sorted PFMPs were cultured for 24 h, and then treated with IL-6 (5 ng/mL) and soluble IL-6 receptor (sIL-6R) (5 ng/mL) for 2 h before RNA extraction and qPCR. IL-6 significantly increased the expression of the transcription factor *Fbxo15* (Fc 4.1 ± 2.1, p < 0.05), while conversely decreasing the expression of *Tlx* (Fc −8.6 ± 0.1, p < 0.01) and lowered the expression levels of *Dnmt1* below detection levels (Figure 2E).

**SVZ NSPs Express Both GP130 and IL-6R**

As we saw changes in the proliferation of specific NSP subsets in response to IL-6, we asked whether the NSPs express GP130 and IL-6 alpha receptor (IL-6Rα), which comprise the IL-6R complex. Neurospheres were established from P5 mice, propagated for 7 days and then analyzed by western blot. As predicted, these NSPs expressed the IL-6R (68 kDa) and GP130 (130 kDa) receptor, as validated by comparing the NSPs with a macrophage cell line (Figure 3A). However, neurospheres are a complex mixture of progenitors and stem cells. Therefore, to establish more precisely which cells within the neurospheres express the IL-6R, we performed flow cytometry, combining antibodies to the IL-6R with the four other antibodies used to characterize the NSPs (Figure 3B). Spleen cells were used as a positive control for the expression of IL-6R. This analysis revealed that BNAP/GRP1, GRP2, MP4, PFMP, and MP2 express IL-6R, whereas receptor expression was below the level of detection for the NSCs, GRP3, and MP1 (Figure 3C). Altogether, these data demonstrate that most SVZ progenitors can be directly stimulated by the cytokine IL-6.
IL-6 Activates pSTAT-3 in SVZ Neural Precursors in the Absence of sIL-6R Trans-signaling

IL-6 can activate downstream signaling in cells in absence of mIL-6R, via a phenomenon known as trans-signaling where sIL-6R associates with gp130; therefore, cells that do not express the IL-6R may still be affected by IL-6. Once the IL-6 binds to gp130 and to the IL-6R, it activates intracellular tyrosine kinases, such as the Janus kinases (JAKs), which then phosphorylate downstream signaling proteins that include Stat1 and Stat3, the RAS-RAF-MAPK pathway, and the phosphatidylinositol 3-kinase pathway. We investigated these downstream signal pathways upon stimulating SVZ NSPs with IL-6 in the presence or absence of sIL-6R. As shown in Figure 3D, IL-6 strongly increased levels of pSTAT3 in the NSPs in the absence of trans-signaling. Interestingly, the related cytokine leukemia inhibitory factor (LIF) increased phosphorylation of both STAT3 and STAT1 (Figures 3E and 3F). A time course study where samples were analyzed for the phosphorylation of STAT1 (E), STAT3 (F) and MAPK (G) at 15, 30, and 120 min after IL-6 addition. Data representative of three independent experiments. Values represent fold change ± SEM. *p < 0.05, **p < 0.01, as analyzed using ANOVA and Tukey's post-hoc test, n = 6.
IL-6 Increases Tripotentility in Neurospheres Containing PDGF-Responsive Progenitors, but Not in Neurospheres Enriched for NSCs

In previous studies, we reported that IL-6 increased the size, number, and self-renewal (beyond four passages) of rat SVZ NSPs compared with controls, which we interpreted as evidence that IL-6 increased the self-renewal of the NSCs (Covey et al., 2011). By contrast, propagating mouse SVZ NSPs at the same cell density and in a medium containing 20 ng/mL epidermal growth factor (EGF), 10 ng/mL FGF-2, and 5 ng/mL IL-6 for 7 days significantly decreased both the number and size of neurospheres formed (Figures 4A1–A3). This reduction was confirmed by dissociating the secondary neurospheres and analyzing the total number of live cells, which revealed a decrease in the total cell yield from neurospheres treated with IL-6 compared with control (IL-6: $1.4 \times 10^6$ versus control: $1.9 \times 10^6$). Staining these neurospheres for astrocyte (glial fibrillary acidic protein [GFAP]), oligodendrocyte (O4), and neuronal (TUJ1) markers revealed that IL-6 increased the proportion of tripotential neurospheres (Figure 4A4; 38.9% control versus 51.6% IL-6) to the detriment of bipotential neurospheres (Figure 4A4; 61.1% control versus 47.3% IL-6). This increase in multipotent cells raised the question whether IL-6 was inducing NSC differentiation toward producing more multipotential progenitors or whether IL-6 was directly affecting the proliferation of multipotential progenitors. To begin answering this question we reduced the cell density to generate clonal neurospheres. As above, NSPs were propagated as neurospheres under 10 ng/mL FGF-2 and 10 ng/mL PDGFaa, by incubation with 10 μM of EdU for 3 h (Figure 5A). The neurospheres were dissociated and analyzed by flow cytometry. Figures 5B–5D shows the gating strategy. Live cells were first gated for NG2+CD140a+, NG2+CD140a–, NG2–CD140a+. Next the NG2–CD140a+ were gated for CD133+Lex+, CD133–Lex+, CD133–Lex– defined in our previous studies (Buono et al., 2012). We then applied the EdU gating to each population. IL-6 treatment increased the percentage of EdU+ PFMPs by 2-fold (Figure 5E; control: 7.98%; IL-6: 17.8%), whereas it decreased the percentage of GRP3 EdU+ cells (control: 27.4%; IL-6: 18.8%), B nap EdU+ cells (control: 19.6%; IL-6: 13.6%), GRP2 EdU+ cells (control: 34.7%; IL-6: 21.3%), MP1 EdU+ cells (control: 20.4%; IL-6: 13.5%), and NSC EdU+ cells (control: 22.1%; IL-6: 12.6%) (Figures 5F–5J).

IL-6 Increases the Proportion of PFMPs In Vitro, at the Expense of NSCs and Other Progenitors

We used our multi-marker flow panel to establish how IL-6 affected the balance of the specific NSP subsets within the neurospheres. As above, NSPs were propagated as neurospheres in standard growth medium or medium supplemented with 5 ng/mL IL-6 + 5 ng/mL of sIL-6R. The proportion of subtypes was quantified by flow cytometry using: CD133/Lex/NG2/CD140a. A total of 20,000–40,000 live cell events were analyzed after excluding debris and dead cells using DAPI. Positively stained cells were classified by comparison with isotype controls. IL-6 significantly increased the percentage of PFMPs (control: 20.90% ± 0.40%; IL-6: 31.90% ± 0.20%) (Table 1; p < 0.001). However, it decreased the proportion of NSCs (control: 0.97% ± 0.011%; IL-6: 0.79% ± 0.027%; p < 0.05), MP1 (control: 4.65% ± 0.03%; IL-6: 3.33% ± 0.15%; p < 0.001), MP2s (control: 9.26% ± 0.16%, IL-6: 7.44% ± 0.10%, p < 0.001), Bnap (control: 40.23% ± 0.33%, IL-6: 34.6% ± 0.45%, p < 0.001), GRP2s (control: 6.91% ± 0.15%, IL-6: 5.76% ± 0.03%, p < 0.05), and GRP3 (control: 5.75% ± 0.12%; IL-6: 6.28% ± 0.08%).

IL-6 Decreased the Output of Forebrain Astrocytes from the SVZ

After establishing that IL-6 modulated SVZ NSP proliferation, we asked whether increased levels of IL-6 would affect the production of neurons or astrocytes by performing fate mapping using an inducible Nestin-CreERT2/Rosa26-TdTomato reporter mouse. TdTomato expression was induced with 75 mg/kg tamoxifen injection at P1. Reporter mice were injected with 75 ng of IL-6 twice on P4 and once on P5. We evaluated TdTomato-expressing cells at P35 in those regions that would be receiving postnatally differentiating SVZ cells, such as the forebrain and olfactory bulbs, and compared cell numbers between IL-6-injected mice and PBS-injected controls. TdTomato+ cells exclusively expressed of multipotentiality previously observed was not driven by IL-6 directly affecting NSCs. Next, we grew neurospheres under 10 ng/mL FGF-2 and 10 ng/mL PDGFaa, to reduce the number of NSCs in favor of PDGF-responsive progenitors. Under these conditions, IL-6 increased the number of neurospheres, while again reducing sphere size (Figure 4 C1–C3). IL-6 treatment also increased the number of tripotential neurospheres (Figure 4C4; 40% control versus 53.33% IL-6).

IL-6 Increases Proliferation of the PFMP In Vitro

To determine how IL-6 was affecting the proliferation of each progenitor and NSCs in vitro, we assessed EdU incorporation into the cultured SVZ NSPs using the multi-marker flow panel described above. SVZ NSPs were treated with 5 ng/mL of IL-6 + 5 ng/mL of sIL-6R for 10 h followed by incubation with 10 μM of EdU for 3 h (Figure 5A). The neurospheres were dissociated and analyzed by flow cytometry. Figures 5B–5D shows the gating strategy. Live cells were first gated for NG2+CD140a+, NG2+CD140a–, NG2–CD140a+. Next the NG2–CD140a+ were gated for CD133+Lex+, CD133–Lex+, CD133–Lex– defined in our previous studies (Buono et al., 2012). We then applied the EdU gating to each population. IL-6 treatment increased the percentage of EdU+ PFMPs by 2-fold (Figure 5E; control: 7.98%; IL-6: 17.8%), whereas it decreased the percentage of GRP3 EdU+ cells (control: 27.4%; IL-6: 18.8%), B nap EdU+ cells (control: 19.6%; IL-6: 13.6%), GRP2 EdU+ cells (control: 34.7%; IL-6: 21.3%), MP1 EdU+ cells (control: 20.4%; IL-6: 13.5%), and NSC EdU+ cells (control: 22.1%; IL-6: 12.6%) (Figures 5F–5J).
formed NeuN+ neurons in the granule cell layer of the olfactory bulb. However, IL-6 treatment had no affect in the number of those cells (Figures 6A and 6C). By contrast, IL-6-treated mice had \( \frac{1}{2} \) fewer postnatally derived astrocytes in the frontal cortex (control: 0.23% ± 11.55%, n = 3; IL-6: 0.1% ± 8.74%, n = 4; p < 0.001) (Figures 6D and 6E), as demonstrated by positive staining for S-100b and negative staining for Olig2 (Figure 6F).

**Figure 4. IL-6 Increases Tripotentiality in Neurospheres Containing PDGF-Responsive Progenitors, but Not in Neurospheres Enriched for NSCs**

Secondary spheres were propagated in 20 ng/mL EGF + 10 ng/mL FGF-2 ± rmIL-6 (5 ng/mL) at different cell densities. (A1, B1, C1) Representative phase-contrast images of spheres from control and IL-6-treated groups at 7 days in vitro (DIV). Scale bars, 400 μm. Neurosphere number and average diameter were quantified at 7 DIV for neurospheres grown from \( 2.5 \times 10^5 \) (A2 and A3), \( 10^4 \) (B2 and B3), and \( 2.5 \times 10^5 \) cells per mL + PDGFα (C2 and C3). Data are representative of three independent experiments with error bars representing mean ± SEM. At least 120 spheres were measured per group. **p < 0.001, ***p < 0.0001, versus control using Student unpaired t test. Neurospheres were differentiated and stained for TuJ1 (neurons) (D1), GFAP (astrocytes) (D2), and O4 (oligodendrocytes) (D3). Scale bars, 50 μm. Thirty spheres from each group were evaluated in each experiment to quantify the number of mono-, bi-, and tripotential spheres (A4, B4, C4). Data are representative of three independent experiments.
Elevated Neonatal IL-6 Leads to an Olfaction Deficit in the Adult Mice

Although there was no difference in the numbers of new olfactory bulb neurons produced after IL-6 treatment, the possibility existed that the new neurons were inappropriately connected. Therefore, IL-6-treated mice were evaluated using the buried food test at P60 (Ziegler et al., 2019). This test revealed a significant deficit in olfaction, where the IL-6-injected animals had a 115% increase in latency in finding a sugary-flavored food compared with PBS-injected controls (171.9 versus 80.3; p < 0.01) (Figure 6B).

DISCUSSION

Many groups have reported an epidemiologic linkage between maternal infection during pregnancy with neurodevelopmental disorders in the offspring, including developmental delay, cerebral palsy, schizophrenia, and autism (Bear and Wu, 2016; Mednick et al., 1988; Zerbo et al., 2015), but how injury- or infection-induced inflammation affects fetal and neonatal brain development is poorly understood. Immune activators, such as LPS and poly(I:C), affects fetal and neonatal brain development is poorly understood. Immune activators, such as LPS and poly(I:C), have been used in the animal models of MIA to highlight the importance of inflammatory cytokines (Shi et al., 2003; Smith et al., 2007). Specifically, the relative expression of pro- and anti-inflammatory cytokines in the fetal brain are important for the precise pathological profile emerging in later life. Several studies have clearly indicated that IL-6 is a key mediator of MIA and developmental problems in fetus. For example, one study suggested that a single injection of IL-6 into pregnant mice can mimic the effects of maternal infection on cognitive and behavioral disorders. Furthermore, administering a function-blocking antibody to IL-6 reversed the behavioral deficits induced by MIA in the poly(I:C) model (Smith et al., 2007). The importance of IL-6 is further supported in an LPS model of MIA, where administering the anti-inflammatory drug Pioglitazone abolished the increase in plasma IL-6 levels and ASD-like behaviors (Kirsten et al., 2018).

In the studies reported here we have begun to test the hypothesis that the proliferation and specification of NSCs and progenitors in the SVZ are altered as a causal component of the development of ASD. To model the increased levels of IL-6 seen with antenatal infections, we established that intraperitoneal injections of 75 ng of IL-6 will increase blood plasma levels of IL-6 by 2-fold. As a consequence, the proliferation of PFMPs increased 2-fold. These multipotent progenitors are likely equivalent to the fetal PDGF-responsive precursors (PRPs) that were shown to be distinct from the NSCs (Chojnacki and Weiss, 2004). They are similar to the PRPs present in the neonatal rat SVZ as described by Moore et al. (2014). This unique and interesting population of neural progenitors has not been well studied. To determine whether IL-6 acts directly on the PFMPs and to establish the underlying mechanisms of action, we demonstrate that the PFMPs (as well as several other SVZ neural progenitors) express IL-6Rα as well as GP130 receptors necessary for downstream IL-6 signaling pathways, and show that IL-6 activates pSTAT3 in these cells. The increased proliferation of PFMPs correlated with enhanced expression of the self-renewal gene Fbxo15 and with decreased expression of Tlx (Nr2e1) and Dnat1. Increased levels of IL-6 not only increased the proportion of PFMPs in the SVZ but also reduced the proportions of NSCs, MP1, BNP/GRP1, and GRP2.

We postulated that the IL-6-mediated increase in PFMP proliferation could be due to increased expression of transcription factors involved in self-renewal of the neural progenitors. Therefore, we sorted PRPs, stimulated them with IL-6 and analyzed the expression of Ascl1, Klf4, Id2, Olig2, Fbxo15, Tlx, and Gsx1, which have been shown to be important for neural progenitor proliferation. Among those genes we saw an increase in Fbxo15, which interestingly, aside from being related to ESC self-renewal and proliferation (Okita et al., 2007), is associated with ASD in patients bearing 18q deletions (O’Donnell et al., 2010). We also found a highly significant decrease in the expression of Tlx (Nr2e1). In the hippocampus, Tlx promotes proliferation of neural progenitors (Shi et al., 2004) and NSCs (Murai et al., 2014; Niu et al., 2011). Consistent with our observation, Tlx was previously shown to be repressed by IL-1β, impairing hippocampal neurogenesis and cognition (O’Leime et al., 2018). Furthermore, Tlx null mice show reduced learning and memory (Zhang et al., 2008), associated with impaired synaptic plasticity (Christie et al., 2006), hippocampal neuroinflammation (Kozareva et al., 2018), and susceptibility to inflammation-related diseases (Zhang et al., 2010).
plasticity. Gogolla et al. (2009) showed that these interneuron-dependent circuit refinement, are crucial for critical period of development. Neocortical GABAergic parvalbumin-positive/inhibitory (E/I) circuit balance during critical periods observed in ASD is attributed to the disruption of excit-cell-type specific. control methylation are developmental and progenitor from that used in previous MIA studies. For example, Gallagher et al. (2013) provided IL-6 to pregnant mice at the equivalent of the human early first trimester. Thus, their intervention would have affected neuroepithelial cells in the VZ. In contrast, we used neonatal mice to study the effects of increased level of IL-6 on SVZ NSPs at the human fetal equivalent of the beginning of the third trimester as it is this time that best correlates with the development of ASD (Zerbo et al., 2015). At this stage of development, the SVZ is expanding rapidly, giving rise to distinct sets of late-developing interneurons and glial progenitors that have been shown to be affected in ASD (Gogolla et al., 2009; Li et al., 2014; Marie et al., 2018).

A central gene controlling epigenetic regulation of gene transcription and chromatin structure, Dnmt1, has been reported to be increased in the brains of mice exposed to diesel exhaust during gestation. Diesel exhaust increases levels of IL-6 in the neonatal brain and produces behavioral outcomes reminiscent of ASD (Chang et al., 2019). In contrast, in our sorted PFMPs, we observed a complete ablation of Dnmt1 expression. The role of DNMT1 in gliogenesis is complicated. Although DNA demethylation is necessary for STAT3 binding to the Gsp promoter, allowing NPCs to respond to astrocyte-inducing cytokines (Takizawa et al., 2001), silencing Dnmt1 in ESCs is not sufficient to induce astrogliogenesis (Urayama et al., 2013). However, Fan et al., (2005) showed that suppressing Dnmt1 in neural progenitors was sufficient to drive precocious astroglial differentiation through an increase in STAT signaling (Fan et al., 2005). By contrast, silencing Dnmt1 in neocortical OPCs suppressed differentiation and induced cell damage (Egawa et al., 2019), suggesting that the mechanisms that control methylation are developmental and progenitor cell-type specific.

One suggested explanation for the diverse phenotype observed in ASD is attributed to the disruption of excitatory/inhibitory (E/I) circuit balance during critical periods of development. Neocortical GABAergic parvalbumin-positive inhibitory neurons, which normally drive experience-dependent circuit refinement, are crucial for critical period plasticity. Gogolla et al. (2009) showed that these interneurons were reduced in the neocortex across multiple genetic and non-genetic ASD mouse models (Gogolla et al., 2009), which would result in decreased numbers of inhibitory synapses. Interestingly, Wei et al. (2012) showed that intraventricular injections of IL-6 reduced the formation of inhibitory synapses and affected dendritic spine plasticity in a mouse model that exhibited an ASD-like behavioral phenotype (Wei et al., 2012).

The experimental paradigm used here is quite different from that used in previous MIA studies. For example, Gallagher et al. (2013) provided IL-6 to pregnant mice at the equivalent of the human early first trimester. Thus, their intervention would have affected neuroepithelial cells in the VZ. In contrast, we used neonatal mice to study the effects of increased level of IL-6 on SVZ NSPs at the human fetal equivalent of the beginning of the third trimester as it is this time that best correlates with the development of ASD (Zerbo et al., 2015). At this stage of development, the SVZ is expanding rapidly, giving rise to distinct sets of late-developing interneurons and glial progenitors that have been shown to be affected in ASD (Gogolla et al., 2009; Li et al., 2014; Marie et al., 2018).

We stably labeled postnatal NSCs to determine whether prenatal inflammation would affect the numbers or types of progeny that they produced in late-developing brain regions. An unexpected result was that olfactory bulb neurogenesis was unaffected in the IL-6-treated mice. In a recently published study, we evaluated SVZ neurogenesis after genetically deleting insulin growth factor II (IGF-II) in adulthood. We reported that this manipulation halved the SVZ NSC numbers, which resulted in an expansion in the progenitor cell pool and with increased numbers of neurons in the olfactory bulb (Ziegler et al., 2019). More recently we have obtained identical results by deleting the insulin receptor in the NSCs in adulthood (Chidambaram et al., in revision for Stem Cell Reports). As the newly added neurons in the olfactory bulb are inhibitory neurons, it was not surprising that the IGF-II and insulin receptor conditional null mice had deficits in olfaction. However, while neonatal IL-6 altered the composition of the SVZ NSP pool, there were no obvious differences in olfactory bulb neurogenesis, suggesting that the cause of the hyposmia is more subtle.

What our fate mapping studies did reveal was a dramatic reduction in frontal neocortical astrocyte production. Changes in glial cell numbers, or in their state of activation, can subsequently increase or decrease synapse numbers (Allen and Eroglu, 2017). A seminal study by Muller and Best (1989) showed that transplanting newborn astrocytes into the adult brain could recover cortical synaptic plasticity in an ocular dominance model (Muller and Best, 1989). Therefore, a viable hypothesis is that reducing the numbers of astrocytes in the forebrain will upset the E/I synaptic balance producing long-lasting behavioral alterations. Supporting this hypothesis, a study that analyzed

---

**Table 1. IL-6 Increases the Proportion of PDGF-Responsive Multipotent Progenitors at Expense of NSCs and Other Progenitors**

|          | NSC       | PFMP      | MP1       | MP2       | BNAP/GRP1 | GRP3   | GRP2   |
|----------|-----------|-----------|-----------|-----------|-----------|--------|--------|
| Control  | 0.97 ± 0.011* | 20.9 ± 0.40 | 4.65 ± 0.03 | 9.26 ± 0.16 | 40.23 ± 0.33 | 5.75 ± 0.12 | 6.91 ± 0.15 |
| IL-6     | 0.79 ± 0.027* | 31.90 ± 0.20*** | 3.33 ± 0.15*** | 7.44 ± 0.10*** | 34.60 ± 0.45*** | 6.28 ± 0.08 | 5.76 ± 0.08* |

Data are the mean percentages for each SVZ NP ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.

*Data represent averages of three independent experiments.
Figure 6. IL-6 Changes the Distribution of SVZ-Derived NSPs in Adult Mice Forebrain and Affects Olfaction

(A) Fluorescence for TdTomato+ (red) and NeuN+ (green) cells in the glomerular (I), mitral (II), and granule cell (III) layers of the olfactory bulb in IL-6-injected mice and PBS-injected controls. Scale bar, 100 μm. The window shows double magnification.

(B) Buried food test. Latency to detect a hidden sugary food pellet (seconds). Error bars represent SEMs from three independent experiments. *p < 0.05 using Student’s t test, comparing IL-6-treated samples with controls.

(C) Number of TdTomato+ cells per mm² in the granule cells layer (expanded detail window). Error bars represent SEMs from 3–5 mice per group.

(D) Frontal cortex from IL-6-injected and control mice showing TdTomato+ (red) and NeuN+ (green) cells. Scale bar, 500 μm.

(E) Number of TdTomato+ cells per mm² in the frontal cortex. Error bars represent SEMs from 3–4 mice per group. *p < 0.01 using Student’s t test.

(F) Confocal image showing co-expression of TdTomato+ and S100b+ cells in astrocytes, and no co-expression of Olig2+. Scale bar, 50 μm.
a large cohort of ASD patient samples to identify ASD candidate genes found that the largest subset included many genes for synaptic transmission. Further analyses showed that many of those genes were involved in glial cell differentiation and were differentially expressed in the corpus callosum of ASD patients (Li et al., 2014).

The observation that neonatal IL-6 exposure reduced astrocyte production was somewhat surprising as earlier studies had shown that IL-6 promoted the differentiation of neocortical progenitors into oligodendrocytes and astrocytes (Bonni et al., 1997; Nakanishi et al., 2007). Islam et al. (2009) demonstrated that IL-6 signaling via STAT3 induced NSCs to differentiate into two types of astrocytes. Furthermore, our own earlier studies had shown that IL-6 synergizes with EGF to increase astrocyte proliferation (Levison et al., 2000). Here, we show that IL-6 reduced the abundance of two bipotential glial-restricted progenitors. Therefore, the most parsimonious explanation for the reduced numbers of astrocytes in the frontal lobe is that this was preceded by a loss in the numbers of these bipotential progenitors. At the present time there are no means to fate map these bipotential glial progenitors; however, we are in the process of validating unique markers for these cells based on an RNA sequencing analysis of FACS-purified SVZ progenitors so that these progenitors may be studied in more depth.

In their work, Gallagher et al. (2013) used the neurosphere assay and reported an increase in SVZ neurosphere-initiating cells cultured from adults exposed to IL-6 as fetuses. By contrast, in our experiments, when neurospheres were exposed to IL-6 in vitro, we observed a reduction of both sphere number and size. Our results also appear to conflict with those of Covey et al., (2011) who showed that IL-6 increased rat SVZ neurosphere number and size. They saw increased production of self-renewing, multipotent progenitors, which was interpreted as an increase in NSCs (Covey et al., 2011). However, neurosphere assays do not allow one to definitely conclude whether a stimulus is increasing the self-renewal and proliferation of NSCs or of multipotential progenitors since the neurosphere assay cannot distinguish between spheres formed by stem cells versus progenitors (Reynolds and Rietze, 2005). To address that question, we show that clonal neurospheres, which are predominantly formed from NSCs, do not show the same increase in potentiality when treated with IL-6. We also show that IL-6 is directly affecting the progenitors by showing that spheres cultured with FGF-2 and PDGF-A (a condition that is not permissive for NSC self-renewal [Chojnacki et al., 2011]), respond to IL-6 with an increase in the number of neuron-generating spheres. This experiment also argues against the conclusion that IL-6 promotes the differentiation of NSCs into tri-potential progenitors.

Our data suggest that the multipotential progenitors affected by IL-6 are probably PDGF responsive; however, different populations of multipotential PDGF-responsive progenitors exist in the postnatal SVZ. Therefore, we used a four-color flow cytometry panel, which can distinguish between eight different cell types found in the SVZ. Using this panel, we show that IL-6 increased the proportion of PFMPs, while simultaneously decreasing the proportion of NSCs within neurospheres in vitro. This result begins to explain how IL-6 treatment can reduce neurosphere number and size, while increasing multipotentiality. We also showed that IL-6 increased the percentage of EdU+ PFMPs by 2-fold compared with the decrease in EdU+ NSCs in vitro and we confirmed our in vitro results in vivo using intraperitoneal injections of IL-6, which increased the percentage of EdU+ PFMPs. We did not see any significant differences in NSC proliferation, but that can be attributed to long cell-cycle length of the NSCs, which was not captured as we evaluated a single time point. Altogether, these data lead to the conclusion that IL-6 expands the PFMPs at the expense of the NSCs.

It is becoming clear that different progenitor cell types are differentially responsive to IL-6 and that IL-6 can either promote or suppress cell proliferation. Monje et al. (2003) showed that the hippocampal neural progenitors expressed IL-6Rs and that an LPS challenge increased hippocampal IL-6R expression. They also showed that IL-6 inhibited hippocampal neurogenesis (Monje et al., 2003). Gallagher et al. (2013) showed IL-6R expression on Sox2+ VZ/SVZ precursors. Our flow cytometry data show that PFMP, MP2, GRP2, MP2, and BNAP express IL-6R, whereas IL-6Rz is not expressed by NSC, MP1, or GRP3. Those cell types that express membrane-bound IL-6R can be stimulated directly by IL-6, whereas the remainder can be stimulated by IL-6, but only through trans-signaling, which requires the sIL-6Rz.

A number of signaling pathways have been shown to be activated by IL-6 in different CNS cell types, such as JAK and, to a lesser extent, TYK, which, in turn, activate downstream signaling proteins STATs. IL-6 can also activate the RAS-RAF-MAPK and the phosphatidylinositol 3-kinase pathways (Boulanger et al., 2003). Studies have investigated the activation of pSTAT1 versus pSTAT3 by IL-6 in highly enriched astrocyte compared with microglial cultures (Hsu et al., 2015). The astrocytes responded with significant increases in both pSTAT1 and pSTAT3, in contrast IL-6-treated microglia activated pSTAT1 significantly, but not pSTAT3. Therefore, we evaluated signal transduction pathways activated in SVZ NSPs in response to IL-6. We found a significant increase in pSTAT3 signal, but not in pSTAT1, in response to IL-6 and no effect on either pAKT or p44/p42 MAPK. Interestingly, LIF activated both STAT1 and STAT3.
Altogether our studies show that increased blood levels of IL-6 dysregulate the NSPs of the mouse SVZ, increasing PFMP proliferation while simultaneously decreasing the percentage of NSCs as well as two bipotential glial-restricted progenitors. This shift in the composition of the forebrain germinal zone progenitors is accompanied by changes in gliogenesis as well as in olfactory sensitivity. Altogether, these studies provide important new insights into the molecular and cellular underpinnings of neurodevelopmental disorders associated with maternal infections.

**EXPERIMENTAL PROCEDURES**

**Materials**

Common laboratory chemicals were purchased from either Sigma or VWR. Cell culture media and supplements were purchased from Invitrogen or Sigma.

**Mice**

C57BL/6 mice were generated in-house from mice purchased from Jackson Laboratory (Bar Harbor, ME). C57BL/6 mice were used for all *in vivo* studies. Only male mice were used for *in vivo* EdU experiments, as ASD is most prevalent in males. All experiments were performed in accordance with protocol 17.064 approved by the IACUC committee of Rutgers University Biomedical Health Sciences.

**IL-6 Injections and ELISA**

P4 Swiss Webster mice were injected twice intraperitoneally with PBS or carrier-free rmIL-6 (R&D Systems, Minneapolis, MN) using a Hamilton syringe separated by 8 h. Trunk blood was collected in 100 USP of Heparin Sodium (Sagent Pharmaceuticals, Schauburg, IL) 2 h after injection. Samples were centrifuged at 2,000 × g for 15 min and then aliquoted and stored at −80°C until analyzed. A mouse IL-6 ELISA Kit (BD OptEIA) was used to analyze the samples.

**Neurosphere Experiments**

Neural progenitors were cultured from SVZs of 4–7-day-old C57BL/6 mice as described previously (Buono et al., 2015). Culture plates for secondary neurospheres were seeded with 2.5 × 10⁵ or 10⁵ cells per mL. Total neurosphere numbers were counted for each experimental replicate under an inverted microscope. Neurosphere diameter was calculated using Zeiss Axiovision and ImageJ software. Cell yield was counted by trypan blue exclusion. Neurospheres were differentiated as described previously and stained with 20 ng/mL EGF and 10 ng/mL FGF-2. Neurospheres were dissociated, propagated for 4 days, and PFMPs were sorted using FACS. Sorted cells were cultured in the absence or presence of rmIL-6 (5 ng/mL) + sIL-6R (5 ng/mL) for 2 h. RNA was isolated using NucleoSpin RNA Plus Kit (Macherey-Nagel), amplified and cDNA generated using iScript cDNA synthesis kit (Bio-Rad). qPCR was performed using 100 ng of cDNA and validated Quantitec SYBR Green primers (Qiagen) on an CFX 96 real-time PCR system (Bio-Rad). 18S RNA and actb were used as normalization controls. Relative quantification was evaluated by the ΔΔ Ct method.

**Western Blots**

Exponentially growing cultures of neural progenitors were treated ± IL-6/sIL-6R for 30 min and harvested at the indicated time points. The cells were washed with ice-cold PBS, then placed into lysis buffer (50 mM Tris-HCl [pH 7.6], 0.1% sodium dodecyl sulfate, 1% Triton X-100) and protease inhibitors. The lysates were sonicated, then clarified by centrifugation at 10,000 × g at 4°C for 15 min. Aliquots of 30–50 μg of protein lysate were fractionated on 4%–12% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The blots were developed using antibodies to the phosphorylated and non-phosphorylated forms of the following signal transduction proteins: pSTAT3, pSTAT1, pMAPK, and AKT (all from Cell Signaling Technology, Danvers, MA). Independent experiments were repeated at least three times. For IL-6R expression, RAW 264.7 cell lysate was used as a positive control. Blots were developed for IL-6Rα and for GP130 (antibodies from R&D Systems) followed by chemiluminescent detection using Western Lightning Plus-ECL (PerkinElmer, Waltham, MA) and ChemiDoc Touch imaging system (Bio-Rad).

**Statistical Analyses**

For all datasets, statistical analyses were performed using Student’s unpaired t test and ANOVA followed by Tukey’s *post hoc* multiple comparison test. A *p* < 0.05 was considered significant. In figures, asterisks denote statistical significance marked by *p* < 0.05, **p** < 0.01, ***p*** < 0.001. GraphPad Prism (version 5.01) was used for all analyses. Sample sizes (n) are indicated in the figure legends.
SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.stemcr.2020.03.019.

AUTHOR CONTRIBUTIONS

E.K. and F.J.V. performed most of the experiments, data analysis, and wrote the manuscript. A.N. performed some neurosphere culture and analysis. V.H.S. and K.D.B. contributed to flow cytometry experiments. All authors reviewed the manuscript. S.W.L. participated in the design of the experiments, supervised the execution of the experiments, oversaw the data analysis, and participated in writing the manuscript.

ACKNOWLEDGMENTS

This work was supported by a grant from the Governor’s Council for Medical Research and Treatment of Autism, CAUT17BSP010 and by an NIH R21, NS107772 awarded to S.W.L.

REFERENCES

Aalten, R., Heikkinen, T., Hakala, K., Laine, K., and Alalen, A. (2005). Transfer of proinflammatory cytokines across term placenta. Obstet. Gynecol. 106, 802–807.
Allen, N.J., and Eroglu, C. (2017). Cell biology of astrocyte-synapse interactions. Neuron 96, 697–708.
Ashwood, P., Krakowiak, P., Hertz-Picciotto, I., Hansen, R., Pessah, I., and Van de Water, J. (2011). Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav. Immun. 25, 40–45.
Atladottir, H.O., Thorsen, P., Ostergaard, L., Schendel, D.E., Lemcke, S., Abbalah, M., and Parner, E.T. (2010). Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J. Autism Dev. Disord. 40, 1423–1430.
Bear, J.J., and Wu, Y.W. (2016). Maternal infections during pregnancy and cerebral palsy in the child. Pediatr. Neurol. 57, 74–79.
Bonni, A., Sun, Y., Nadal-Vicens, M., Bhatt, A., Frank, D.A., Rozovsky, I., Stahl, N., Yancopoulos, G.D., and Greenberg, M.E. (1997). Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 278, 477–483.
Boulanger, M.J., Chow, D.C., Brevnova, E.E., and Garcia, K.C. (2003). Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300, 2101–2104.
Buono, K.D., Goodus, M.T., Guardia Clausi, M., Jiang, Y., Loporchio, D., and Levison, S.W. (2015). Mechanisms of mouse neural precursor expansion after neonatal hypoxia-ischemia. J. Neurosci. 35, 8855–8865.
Buono, K.D., Vadlamuri, D., Gan, Q., and Levison, S.W. (2012). Leukemia inhibitory factor is essential for subventricular zone neural stem cell and progenitor homeostasis as revealed by a novel flow cytometric analysis. Dev. Neurosci. 34, 449–462.
Chang, Y.C., Daza, R., Hevner, R., Costa, L.G., and Cole, T.B. (2019). Prenatal and early life diesel exhaust exposure disrupts cortical lamina organization: evidence for a reelin-related pathogenic pathway induced by interleukin-6. Brain Behav Immun 78, 105–115.
Chen, H., Goodus, M., de Toledo, S., Azzam, E., Levison, S., and Souayah, N. (2015). Ionizing radiation perturbs cell cycle progression of neural precursors in the subventricular zone without affecting their long-term self-renewal. ASN Neuro 2015, 1–16.
Chojnacki, A., Mak, G., and Weiss, S. (2011). PDGFRalpha expression distinguishes GFAP-expressing neural stem cells from PDGFR-responsive neural precursors in the adult periventricular area. J. Neurosci. 31, 9503–9512.
Chojnacki, A., and Weiss, S. (2004). Isolation of a novel platelet-derived growth factor-responsive precursor from the embryonic ventral forebrain. J. Neurosci. 24, 10888–10899.
Christie, B.R., Li, A.M., Redila, V.A., Booth, H., Wong, B.K., Eadie, B.D., Ernst, C., and Simpson, E.M. (2006). Deletion of the nuclear receptor Nr2e1 impairs synaptic plasticity and dendritic structure in the mouse dentate gyrus. Neuroscience 137, 1031–1037.
Covey, M.V., Loporchio, D., Buono, K.D., and Levison, S.W. (2011). Opposite effect of inflammation on subventricular zone versus hippocampal precursors in brain injury. Ann. Neurol. 70, 616–626.
Croonenberghs, J., Bosmans, E., Deboutte, D., Kenis, G., and Maes, M. (2002). Activation of the inflammatory response system in autism. Neuropsychobiology 45, 1–6.
Egawa, N., Shindo, A., Hikawa, R., Kinoshita, H., Liang, A.C., Itoh, K., Lok, J., Maki, T., Takahashi, R., Lo, E.H., et al. (2019). Differential roles of epigenetic regulators in the survival and differentiation of oligodendrocyte precursor cells. Glia 67, 718–728.
Fan, G., Martinowich, K., Chin, M.H., He, E., Fouse, S.D., Hutnick, L., Hattori, D., Ge, W., Shen, Y., Wu, H., et al. (2005). DNA methylation controls the timing of astrogliogenesis through regulation of JAK-STAT signaling. Development 132, 3345–3356.
Gallagher, D., Norman, A.A., Woodard, C.L., Yang, G., Gauthier-Fisher, A., Fujitani, M., Vessey, J.P., Cancino, G.I., Sachewsky, N., Woltjen, K., et al. (2013). Transient maternal IL-6 mediates long-lasting changes in neural stem cell pools by deregulating an endogenous self-renewal pathway. Cell Stem Cell 13, 564–576.
Gogolla, N., Leblanc, J.J., Quast, K.B., Sudhof, T.C., Fagiolini, M., and Hensch, T.K. (2009). Common circuit defect of excitatory-inhibitory balance in mouse models of autism. J. Neurodev Disord. 1, 172–181.
Gomez, R., Romero, R., Ghezzi, F., Yoon, B.H., Mazor, M., and Berry, S.M. (1998). The fetal inflammatory response syndrome. Am. J. Obstet. Gynecol. 179, 194–202.
Hsu, M.-P., Frausto, R., Rose-John, S., and Campbell, I.L. (2015). Analysis of IL-6/gp130 family receptor expression reveals that in contrast to astroglia, microglia lack the oncostatin M receptor and functional responses to oncostatin M. Glia 63, 132–141.
Islam, O., Gong, X., Rose-John, S., and Heese, K. (2009). Interleukin-6 and neural stem cells: more than gliogenesis. Mol. Biol. Cell 20, 188–189.
Kirsten, T.B., Casarin, R.C., Bernardi, M.M., and Felicio, I.F. (2018). Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway. PLoS One 13, e0197060.

Kozareva, D.A., Hueston, C.M., O’Le ime, C.S., Crotty, S., Dockery, P., Cryan, J.F., and Nolan, Y.M. (2017). Absence of the neurogene-

Lee, B.K., Magnusson, C., Gardner, R.M., Blomstrom, A., Newschaffer, C.J., Burstyn, I., Karlsson, H., and Dalman, C. (2015). Maternal hospitalization with infection during pregnancy and risk of autism spectrum disorders. Brain Behav. Immun. 44, 100–105.

Levison, S.W., Jiang, F.J., Stoltzfs, O.K., and Ducceschi, M.H. (2000). IL-6-type cytokines enhance epidermal growth factor-stim-

Li, J., Shi, M., Ma, Z., Zhao, S., Euskirchen, G., Ziskin, J., Urban, A., Hallmayer, J., and Snyder, M. (2014). Integrated systems analysis reveals a molecular network underlying autism spectrum disor-

Malkova, N.V., Yu, C.Z., Hsiao, E.Y., Moore, M.J., and Patterson, P.H. (2012). Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav. Immun. 26, 607–616.

Marie, C., Clavairoly, A., Frah, M., Hmidan, H., Yan, J., Zhao, C., Van Steenwinckel, J., Daveau, R., Zalc, B., Hassan, B., et al. (2018). Oligodendrocyte precursor survival and differentiation requires chromatin remodeling by Chd7 and Chd8. Proc. Natl. Acad. Sci. U S A 115, E8246–E8255.

Mednick, S.A., Machon, R.A., Huttunen, M.O., and Bonett, D. (1988). Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch. Gen. Psychiatry 45, 189–192.

Meyer, U., Nyffeler, M., Engler, A., Uwryker, A., Schedlowski, M., Knuese, I., Yee, B.K., and Feldon, J. (2006). The time of prenatal immi-

Monje, M.L., Toda, H., and Palmer, T.D. (2003). Inflammatory blockade restores adult hippocampal neurogenesis. Science 302, 1760–1765.

Moore, L., Bain, J.M., Loh, J.M., and Levison, S.W. (2014). PDGF-

Murai, K., Qu, Q., Sun, G., Ye, P., Li, W., Asuelime, G., Sun, E., Tsai, G.E., and Shi, Y. (2014). Nuclear receptor TLX stimulates hippocampal neurogenesis and enhances learning and memory in a transgenic mouse model. Proc. Natl. Acad. Sci. U S A 111, 9115–9120.

Nakanishi, M., Niidome, T., Matsuda, S., Akaite, A., Kihara, T., and Sugimoto, H. (2007). Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells. Eur. J. Neurosci. 25, 649–658.

Niu, W., Zou, Y., Shen, C., and Zhang, C.L. (2011). Activation of postnatal neural stem cells requires nuclear receptor TLX. J. Neurosci. 31, 13816–13828.

O’Donnell, L., Solieau, B., Heard, P., Carter, E., Sebold, C., Gelfond, J., Hale, D.E., and Cody, J.D. (2010). Genetic determinants of autism in individuals with deletions of 18q. Hum. Genet. 128, 155–164.

O’Leary, J.D., Kozareva, D.A., Hueston, C.M., O’Leary, O.F., Cryan, J.F., and Nolan, Y.M. (2016). The nuclear receptor Tlx regulates motor, cognitive and anxiety-related behaviours during adolescence and adulthood. Behav. Brain Res. 306, 36–47.

O’Leime, C.S., Hoban, A.E., Hueston, C.M., Stillling, R., Moloney, G., Cryan, J.F., and Nolan, Y.M. (2018a). The orphan nuclear receptor TLX regulates hippocampal transcriptome changes induced by IL-1beta. Brain Behav. Immun. 70, 268–279.

O’Leime, C.S., Kozareva, D.A., Hoban, A.E., Long-Smith, C.M., Cryan, J.F., and Nolan, Y.M. (2018b). TLX is an intrinsic regulator of the negative effects of IL-1beta on proliferating hippocampal neural progenitor cells. FASEB J. 32, 613–624.

Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Generation of germine-competent induced pluripotent stem cells. Nature 448, 313–317.

Reynolds, B.A., and Rietze, R.L. (2005). Neural stem cells and neuro-

Shi, L., Fatemi, S.H., Sidwell, R.W., and Patterson, P.H. (2003). Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J. Neurosci. 23, 297–302.

Shi, Y., Chichung Lie, D., Taupin, P., Nakashima, K., Ray, J., Yu, R.T., Gage, F.H., and Evans, R.M. (2004). Expression and function of orphan nuclear receptor TLX in adult neural stem cells. Nature 427, 78–83.

Smith, S.E., Li, J., Garbett, K., Mirnics, K., and Patterson, P.H. (2007). Maternal immune activation alters fetal brain development through interleukin-6. J. Neurosci. 27, 10695–10702.

Takizawa, T., Nakashima, K., Namihira, M., Ochiai, W., Uemura, A., Yanagisawa, M., Fujita, N., Nakao, M., and Taga, T. (2001). DNA methylation is a critical cell-intrinsic determin-

Urayama, S., Seml, K., Sanosaka, T., Hori, Y., Namihira, M., Ko-

Wei, H., Chadman, K.K.,McCloskey,D.P.,Sheikh,A.M.,Malik,M., Brown,W.T., and Li, X. (2012). Brain IL-6 elevation causes neuronal circuitry imbalances and mediates autism-like behaviors. Biochim. Biophys. Acta 1822, 831–842.

Wu, W.L., Hsiao, E.Y., Yan, Z., Mazmanian, S.K., and Patterson, P.H. (2017). The placental interleukin-6 signaling controls fetal brain development and behavior. Brain Behav. Immun. 62, 11–23.
Yang, C.J., Liu, C.L., Sang, B., Zhu, X.M., and Du, Y.J. (2015). The combined role of serotonin and interleukin-6 as biomarker for autism. Neuroscience 284, 290–296.

Young, K.A., Berry, M.L., Mahaffey, C.L., Saionz, J.R., Hawes, N.L., Chang, B., Zheng, Q.Y., Smith, R.S., Bronson, R.T., Nelson, R.J., et al. (2002). Fierce: a new mouse deletion of Nr2e1; violent behaviour and ocular abnormalities are background-dependent. Behav. Brain Res. 132, 145–158.

Zaretsky, M.V., Alexander, J.M., Byrd, W., and Bawdon, R.E. (2004). Transfer of inflammatory cytokines across the placenta. Obstet. Gynecol. 103, 546–550.

Zerbo, O., Qian, Y., Yoshida, C., Grether, J.K., Van de Water, J., and Croen, L.A. (2015). Maternal infection during pregnancy and autism spectrum disorders. J. Autism Dev. Disord. 45, 4015–4025.

Zhang, C.L., Zou, Y., He, W., Gage, F.H., and Evans, R.M. (2008). A role for adult TLX-positive neural stem cells in learning and behaviour. Nature 451, 1004–1007.

Ziegler, A.N., Feng, Q., Chidambaram, S., Testai, J.M., Kumari, E., Rothbard, D.E., Constancia, M., Sandovici, I., Cominski, T., Pang, K., et al. (2019). Insulin-like growth factor II: an essential adult stem cell niche constituent in brain and intestine. Stem Cell Reports 12, 816–830.